Amgen Inc (AMGN) Stock Price, Quote & News

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 805 447 1000

Fax: 805 447 1010

Website: www.amgen.com

Address:

One Amgen Center Drive, Thousand Oaks, United States

Sunny3999 Feb. 24 at 8:38 PM

$PMN take look at the war chest $ABBV $AMGN $CELG $GILD

0 · Reply

Sunny3999 Feb. 24 at 8:07 PM

$PMN last call before take off $ABBV $AMGN $CELG $GILD

0 · Reply

YourfrenPepe420 Feb. 24 at 7:01 PM

$IBRX is the next $AMGN $100-300 in 2-4 yrs

1 · Reply

REDBEAR Feb. 24 at 5:01 PM

$AMGN added to long term hold on the breakout, i think it will be a good year.

1 · Reply

inspector_gadget86 Feb. 23 at 2:16 PM

$AMGN $HIMS $LLY $NVO Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

0 · Reply

AStrokeOfLuck Feb. 21 at 3:48 PM

$XBI $AMGN $BIIB $LABU $PILL

1 · Reply

KenFaulkenberry Feb. 20 at 3:48 PM

$AMGN Amgen (AMGN) Stock Analysis Amgen combines steady cash flow from blockbuster drugs with long-term upside potential from its research pipeline and strategic acquisitions. Its history of increasing dividends and share repurchases appeals to income and total return investors alike. For those seeking exposure to the biotech sector with lower volatility and a shareholder-friendly focus, Amgen represents a good large-cap opportunity. Is the stock price a Buy, Sell, or Hold? What is the Intrinsic Value of AMGN? https://dividendvaluebuilder.com/amgen-amgn-dividend-stock-analysis/

0 · Reply

erevnon Feb. 20 at 3:37 PM

Barclays initiates coverage on Amgen $AMGN at Equal-Weight rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

clan Feb. 20 at 2:59 PM

$MNKD @DRFSR @pierrules more Yabba-dabba-doos are incoming... ... for the good of all Mannkind! $SPY $UTHR $AMGN

1 · Reply

OfficialStocktwitsUser Feb. 19 at 9:07 PM

$AMGN RSI: 67.93, MACD: 11.1006 Vol: 15.24, MA20: 357.67, MA50: 338.14 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

Feb 23, 2026, 5:12 AM EST - 1 day ago

Harbor Large Cap Value Fund Q4 2025 Portfolio Review

CBSH COF DHR LEN MRK MSFT PH

Feb 18, 2026, 6:14 PM EST - 6 days ago

Amgen Inc. (AMGN) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Feb 13, 2026, 4:01 PM EST - 11 days ago

AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

Feb 13, 2026, 6:13 AM EST - 11 days ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

LLY NVO PFE

Feb 12, 2026, 7:34 PM EST - 12 days ago

Amgen Inc. (AMGN) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

Feb 12, 2026, 8:05 AM EST - 12 days ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AVGO BAC BK BMY

Feb 11, 2026, 4:06 PM EST - 13 days ago

2 Urgent Sells And 2 No Brainer Dividend Buys

ABBV AEP BMY ESS HASI HD PFE

Feb 5, 2026, 11:55 AM EST - 19 days ago

CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists

CVS LLY

Feb 4, 2026, 10:50 AM EST - 20 days ago

Why Amgen Stock Is Paying Off Big For Long-Term Investors

Feb 4, 2026, 7:55 AM EST - 20 days ago

Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge

Feb 3, 2026, 8:20 PM EST - 21 days ago

Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 4:58 PM EST - 21 days ago

Amgen Logs Higher Fourth-Quarter Revenue on Double-Digit Volume Boost

Feb 3, 2026, 4:05 PM EST - 21 days ago

Amgen quarterly results beat Street estimates on higher sales, lower tax rate

Feb 3, 2026, 4:01 PM EST - 21 days ago

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Feb 3, 2026, 1:27 PM EST - 21 days ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT GPCR LLY NVO PFE VKTX

Jan 30, 2026, 1:09 PM EST - 25 days ago

Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends

Jan 28, 2026, 4:01 PM EST - 27 days ago

AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Jan 22, 2026, 11:15 AM EST - 4 weeks ago

Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential

Jan 20, 2026, 11:34 AM EST - 5 weeks ago

Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access

Jan 15, 2026, 4:40 PM EST - 5 weeks ago

Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing

Jan 14, 2026, 12:36 PM EST - 5 weeks ago

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Jan 13, 2026, 7:55 PM EST - 6 weeks ago

Amgen CEO Bob Bradway goes one-on-one with Jim Cramer

Jan 13, 2026, 7:51 PM EST - 6 weeks ago

Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss

Jan 13, 2026, 6:54 PM EST - 6 weeks ago

Amgen CEO says weight loss drug can address 'patient persistence issue'

Jan 13, 2026, 10:22 AM EST - 6 weeks ago

Ro partners with Amgen to study barriers to obesity care, GLP-1 access

Jan 12, 2026, 9:16 PM EST - 6 weeks ago

Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:42 PM EST - 6 weeks ago

Amgen says MariTide helped trial patients maintain weight loss

Jan 12, 2026, 6:46 PM EST - 6 weeks ago

Amgen to announce data on obesity drug MariTide at healthcare conference

Jan 11, 2026, 7:40 AM EST - 6 weeks ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

CVX HD JNJ KO MRK NKE PG

Jan 10, 2026, 9:52 AM EST - 6 weeks ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

CRM DIS HD HON JNJ KO MRK

Jan 9, 2026, 12:57 PM EST - 6 weeks ago

Healthy Returns: What to expect from pharma at the JPM conference

AZN BMY LLY MRK NVO PFE

Jan 7, 2026, 4:01 PM EST - 6 weeks ago

AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Jan 7, 2026, 1:45 PM EST - 6 weeks ago

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

Jan 6, 2026, 9:00 AM EST - 7 weeks ago

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE

Jan 2, 2026, 5:06 PM EST - 7 weeks ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

CVX HD JNJ KO MRK NKE PG

Dec 31, 2025, 12:12 PM EST - 7 weeks ago

These three ‘Dogs of the Dow' stocks are must-own for 2026

HD VZ

Dec 26, 2025, 10:35 PM EST - 2 months ago

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

CVX KMB ABM ABT AVGO BCPC BEN

Dec 26, 2025, 1:03 PM EST - 2 months ago

Can Amgen Sustain Its Rally In 2026

Dec 19, 2025, 6:25 PM EST - 2 months ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY ARGX AZN IBB

Dec 19, 2025, 4:09 PM EST - 2 months ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK MRK GILD NVS SNY

Dec 19, 2025, 3:14 PM EST - 2 months ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

BMY GILD GSK MRK NVS SNY

Dec 19, 2025, 2:34 PM EST - 2 months ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

BMY GILD GSK MRK NVS SNY

Dec 19, 2025, 2:23 PM EST - 2 months ago

AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS

Dec 19, 2025, 10:45 AM EST - 2 months ago

Trump to announce new drug-pricing deals later today

ABBV AZN BMY GILD LLY MRK NVO

Dec 17, 2025, 4:11 PM EST - 2 months ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AZN BMY LLY NVS PFE

Dec 12, 2025, 12:43 PM EST - 2 months ago

FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease

Dec 11, 2025, 6:09 PM EST - 2 months ago

FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS

Dec 9, 2025, 4:01 PM EST - 2 months ago

AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND

Dec 3, 2025, 5:23 PM EST - 2 months ago

Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Sunny3999 Feb. 24 at 8:38 PM

$PMN take look at the war chest $ABBV $AMGN $CELG $GILD

0 · Reply

Sunny3999 Feb. 24 at 8:07 PM

$PMN last call before take off $ABBV $AMGN $CELG $GILD

0 · Reply

YourfrenPepe420 Feb. 24 at 7:01 PM

$IBRX is the next $AMGN $100-300 in 2-4 yrs

1 · Reply

REDBEAR Feb. 24 at 5:01 PM

$AMGN added to long term hold on the breakout, i think it will be a good year.

1 · Reply

inspector_gadget86 Feb. 23 at 2:16 PM

$AMGN $HIMS $LLY $NVO Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

0 · Reply

AStrokeOfLuck Feb. 21 at 3:48 PM

$XBI $AMGN $BIIB $LABU $PILL

1 · Reply

KenFaulkenberry Feb. 20 at 3:48 PM

0 · Reply

erevnon Feb. 20 at 3:37 PM

Barclays initiates coverage on Amgen $AMGN at Equal-Weight rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

clan Feb. 20 at 2:59 PM

$MNKD @DRFSR @pierrules more Yabba-dabba-doos are incoming... ... for the good of all Mannkind! $SPY $UTHR $AMGN

1 · Reply

OfficialStocktwitsUser Feb. 19 at 9:07 PM

0 · Reply

StreetwiseReports Feb. 19 at 6:37 PM

New Data, Analyst Calls, and Pipeline Milestones Put Spotlight on Next Wave of Weight-Loss Drug Developers https://ow.ly/kwr850Yik9c Eli Lilly ($LLY:NYSE), Amgen ($AMGN:NASDAQ), and Structure Therapeutics ($GPCR:NASDAQ) were cited in recent reports and corporate updates tied to the expanding GLP-1 and obesity treatment market. Analyst commentary, clinical developments, and pipeline milestones highlighted ongoing activity across the sector.

0 · Reply

SuperGreenToday Feb. 19 at 2:13 AM

$AMGN Share Price: $379.74 Contract Selected: Mar 13, 2026 $380 Calls Buy Zone: $7.57 – $9.35 Target Zone: $14.30 – $17.48 Potential Upside: 79% ROI Time to Expiration: 22 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Sunny3999 Feb. 18 at 5:12 PM

$PMN NEXT STOP $50 $ABBV $AMGN $CELG $GILD

0 · Reply

Quantumup Feb. 18 at 1:28 PM

Truist reiterated $VRDN Buy-$40 and said, REVEAL-1 Topline Preview: Ele' Positioned to Hit Proptosis Bar, after its KOLs check. $AMGN $IMVT - ROIV NVS $ALMS $TRML Truist additionally said, Ahead of VRDN's REVEAL-1 topline for elegrobart (Ele', fka VRDN-003 SC), a half-life extended, SC, IGF-1Ra for active TED, we checked in with KOLs for updated views on Ele' and the broader story. While management targets a 50-70% placebo-adjusted proptosis responder rate, physicians would accept the low end given the strong convenience advantage. Ele' is seen as a potential "game-changer" particularly in chronic and low-CAS patients. A REVEAL-1 win would meaningfully de-risk REVEAL-2 in 2Q and support our ~ $1.3B peak revenue est. Our check-in on volatility surface and the options book for VRDN aligns with our positive views, NT and LT. Reiterate Buy, $40 PT.

0 · Reply

erevnon Feb. 18 at 1:09 PM

Piper Sandler maintains Amgen $AMGN at Overweight and raises the price target from $381 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

AStrokeOfLuck Feb. 17 at 6:21 PM

$AMGN

0 · Reply

Punit Feb. 17 at 6:10 PM

$AMGN AMGEN LAUNCHES $4 BLN FOUR-TRANCHE DEBT OFFERING

0 · Reply

LiveSquawk Feb. 17 at 4:32 PM

$AMGN | Moody's Ratings Assigns Baa1 Rating To Amgen's Notes; Stable Outlook https://www.moodys.com/research/Moodys-Ratings-assigns-Baa1-rating-to-Amgens-notes-stable-outlook-Rating-Action--PR_519588

0 · Reply

EingeLTrade Feb. 17 at 3:16 PM

Top of the channel once again for $AMGN

0 · Reply

Fabiola_T Feb. 17 at 2:09 PM

$AMGN 369 pre flat near 385.12 cap, I’m short, sell the rip

0 · Reply

harmongreg Feb. 17 at 1:50 PM

Dragonfly Capital - 4 Trade Ideas for Amgen: Bonus Idea https://dragonflycap.com/4-trade-ideas-for-amgen-bonus-idea-10/ $AMGN

0 · Reply

JuggernautRaider Feb. 16 at 2:31 PM

$TNXP $NVS $BMY $AMGN to give you an idea of how much the weather impacted TRxs and pharma sales at the end of January, check out this chart of Cosentyx TRxs (and other oral drugs like Otezla and Sotyktu). Check out the far right of the chart which represents the last two weeks of January: sales plummeted for these mature brands as they did for virtually every drug at the end of January, and the terrible weather during the first half of February will likely suppress sales. This leads to an extended buying opportunity for smaller biotechs like Tonix that are insanely undervalued - once the weather subsides, the launch will likely resume impressive growth 🚀

5 · Reply

Market Cap	204.53B
Revenue (ttm)	36.75B
Net Income (ttm)	7.71B
EPS (ttm)	N/A
PE Ratio	17.15
Forward PE	16.75
Profit Margin	20.98%
Debt to Equity Ratio	6.31

Volume	2,454,800
Avg Vol	2,897,116
Day's Range	N/A - N/A
Shares Out	539.07M
Stochastic %K	99%
Beta	0.46
Analysts	Sell
Price Target	$354.86